Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Aug 18, 2026Reported sale · Form 4ADEOYE Y OLUKOTUN · $173.9KOpen the filing ↗
- Aug 18, 2026Reported sale · Form 4MICHAEL S PERRY · $1.0MOpen the filing ↗
- Aug 18, 2026Notice of sale · Form 144Adeoye Olukotun · Director · $173.9KOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record1,18319 flagged findings
Reported transactions (Form 4)55since Jan 10, 2023 · and 5 other holdings
Corporate events (8-K)30since Dec 18, 2019
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-07share offering or dilution eventrecentOpen filing ↗“…into the Amended and Restated Sale Agreement with Jefferies LLC, acting as sales agent and/or principal, which amended and…”
+1 more passage from the same document
- “…Credit facility 40,000 40,000 Other liabilities 11,205 10,811 Total current liabilities 295,220 195,487 Long-term liabilities: Lease…”
- 2026-05-07capital return (buybacks/dividends)recentOpen filing ↗“…the United States, United Kingdom, European Union, Japan and China. The Financing Agreement contains certain embedded features that…”
+1 more passage from the same document
- “…United States, United Kingdom, European Union, Japan and China. The Financing Agreement contains certain embedded features that were…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 1,183)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
Notice of proposed sale · 2 Form 144 filingsshow all 2hide
- Aug 18, 26Form 144 ↗Notice of proposed sale
- Aug 18, 26Form 144 ↗Notice of proposed sale
- Aug 14, 26SCHEDULE 13G/A ↗Passive stake · Avoro Capital Advisors LLC · 9.6% · event on Jun 30, 26 · amendment
- Aug 4, 268-K ↗Current report · Results
- Aug 4, 2610-Q ↗Quarterly report
- Jul 31, 26SCHEDULE 13G/A ↗Passive stake · Vanguard Portfolio Management · 4.5% · event on Jun 30, 26 · amendment
- Jul 27, 26SCHEDULE 13G/A ↗Passive stake · BlackRock, Inc. · 10.1% · event on Jun 30, 26 · amendment
- Jun 17, 26Form 4 ↗Insider transaction
- Jun 17, 26Form 3 ↗Insider transaction
- Jun 16, 268-K ↗Current report · A senior executive left or was appointed
Notice of proposed sale · 3 Form 144/A filingsshow all 3hide
- May 19, 26Form 144/A ↗Notice of proposed sale · amendment
- May 19, 26Form 144/A ↗Notice of proposed sale · amendment
- May 19, 26Form 144/A ↗Notice of proposed sale · amendment
- May 14, 26Form 4 ↗Insider transaction
- May 12, 26Form 144 ↗Notice of proposed sale
- May 7, 2610-Q ↗Quarterly report
- May 7, 268-K ↗Current report · Results
- May 6, 26SCHEDULE 13G ↗Passive stake · FMR LLC · 5.2% · event on Mar 31, 26
- Apr 29, 26SCHEDULE 13G ↗Passive stake · Vanguard Capital Management · 5.0% · event on Mar 31, 26
- Apr 28, 26SCHEDULE 13G ↗Passive stake · Vanguard Portfolio Management · 5.2% · event on Mar 31, 26
- Apr 24, 26SCHEDULE 13G/A ↗Passive stake · BlackRock, Inc. · 12.2% · event on Mar 31, 26 · amendment
1,183 filings on record, the oldest from Aug 7, 98.
Listing the 25 most recent filings of the 1,183 on record.
1111046
- Jun 16, 26A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
3 material agreements entered2025 – 2026show all 3hide
- Jan 12, 26Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Jan 9, 26Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Sep 2, 25Entered a material agreement+1 more in the same filing8-K 1.01 ↗
6 senior executive changes2024 – 2025show all 6hide
- Apr 15, 25A senior executive left or was appointed8-K 5.02 ↗
- Feb 7, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Dec 18, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Mar 18, 24A senior executive left or was appointed8-K/A 5.02 ↗
- Feb 22, 24A senior executive left or was appointed8-K 5.02 ↗
- Jan 22, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jan 4, 24Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Dec 5, 23Auditor change filing (8-K Item 4.01)+1 more in the same filing8-K 4.01 ↗
- Feb 15, 23A material agreement was terminated+2 more in the same filing8-K 1.02 ↗
- Feb 14, 23A senior executive left or was appointed8-K 5.02 ↗
- Feb 6, 23Completed an acquisition or disposal+1 more in the same filing8-K 2.01 ↗
- Dec 8, 22Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Nov 10, 22Entered a material agreement8-K 1.01 ↗
4 senior executive changes2021 – 2022show all 4hide
- Jul 20, 22A senior executive left or was appointed8-K 5.02 ↗
- Jun 6, 22A senior executive left or was appointed8-K 5.02 ↗
- May 5, 22A senior executive left or was appointed8-K 5.02 ↗
- Aug 27, 21A senior executive left or was appointed8-K 5.02 ↗
- Jun 22, 21Entered a material agreement+2 more in the same filing8-K 1.01 ↗
6 older filings not shown · The record reaches back to Sep 10, 04.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- Nov 15, 11Listing notice (8-K 3.01)8-K 3.01 ↗
- Jun 9, 11Listing notice (8-K 3.01)8-K 3.01 ↗
- Dec 14, 10Listing notice (8-K 3.01)8-K 3.01 ↗
- Mar 19, 10Listing notice (8-K 3.01)8-K 3.01 ↗
- Sep 21, 09Listing notice (8-K 3.01)8-K 3.01 ↗
- Aug 10, 09Listing notice (8-K 3.01)+2 more in the same filing8-K 3.01 ↗
- May 27, 09Listing notice (8-K 3.01)+1 more in the same filing8-K 3.01 ↗
- Mar 9, 09Listing notice (8-K 3.01)+1 more in the same filing8-K 3.01 ↗
- Jan 23, 09Restructuring plan with committed costs8-K 2.05 ↗
- Jun 9, 05Write-down of assets+3 more in the same filing8-K 2.06 ↗
The full record holds 11 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13D: stake and stated purpose
Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.
- Sarepta Therapeutics, Inc.9.5%Feb 7, 25SCHEDULE 13D ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- The Vanguard Group11.2%Jun 30, 25SCHEDULE 13G/A ↗
- BlackRock, Inc.10.1%Jun 30, 26SCHEDULE 13G/A ↗3 earlier filings
- Avoro Capital Advisors LLC9.6%Jun 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
- FMR LLC5.2%Mar 31, 26SCHEDULE 13G ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
- Vanguard Capital Management5.0%Mar 31, 26SCHEDULE 13G ↗
show 2 more holdershide
- STATE STREET CORPORATION4.6%Jun 30, 25SCHEDULE 13G ↗1 earlier filing
- Vanguard Portfolio Management4.5%Jun 30, 26SCHEDULE 13G/A ↗1 earlier filing
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Aug 18, Adeoye Olukotun filed notice of intent to sell up to $174K.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $174K on Aug 18, per their Form 4. That is 100% of the shares announced so far, and the window is still open.
View notice (Form 144) ↗+1 more recent notices · 1 with a later sale
- Aug 18, 26Sell$174KADEOYE Y OLUKOTUN↗
- Aug 18, 26Sell$1.0MMICHAEL S PERRY↗
- May 12, 26Sell$228KHongbo Lu↗
- Apr 23, 26Sell$750KJames C HamiltonChief Medical Officer↗
- Apr 22, 26Sell$225KDaniel Joseph ApelChief Financial Officer↗
- Apr 22, 26Sell$82KDaniel Joseph ApelChief Financial Officer↗
- Apr 22, 26Sell$628KDaniel Joseph ApelChief Financial Officer↗
- Mar 5, 26Sell$642KJames C HamiltonChief Medical Officer↗
- Jan 5, 26Sell$283KJames C HamiltonChief Medical Officer↗
- Jan 5, 26Sell$379KJames C HamiltonChief Medical Officer↗
- Jan 5, 26Sell$932KJames C HamiltonChief Medical Officer↗
- Jan 5, 26Sell$813KJames C HamiltonChief Medical Officer↗
There are 17 more transactions in this stretch.
Stock compensation, tax and giftsshow the 11 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Jun 15, 26Compensationamount n/aMatthew Gregory Cohen↗
- Jan 6, 26Compensationamount n/aJames C HamiltonChief Medical Officer↗
- Jan 6, 26Compensationamount n/aDaniel Joseph ApelChief Financial Officer↗
- Jan 6, 26Giftamount n/aPatrick O'BrienCOO↗
- Jan 6, 26Giftamount n/aPatrick O'BrienCOO↗
- Jan 6, 26Giftamount n/aPatrick O'BrienCOO↗
- Jan 6, 26Giftamount n/aPatrick O'BrienCOO↗
- Jan 6, 26Giftamount n/aPatrick O'BrienCOO↗
- Jan 6, 26Compensationamount n/aPatrick O'BrienCOO↗
- Dec 31, 25Giftamount n/aPatrick O'BrienCOO↗
- Dec 31, 25Giftamount n/aPatrick O'BrienCOO↗
The full record holds 251 transactions and goes back to Jan 3, 23.
Its sector and its market
Arrowhead Pharmaceuticals Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Arrowhead Pharmaceuticals Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Arrowhead Pharmaceuticals Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 1,183 documents on file, from Aug 7, 1998 to Aug 20, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.